Revolution and Allogene’s equity financings are a microcosm of biotech’s historic struggle.
ApexOnco Front Page
Recent articles
The company will start its confirmatory bexobrutideg study in June.
Armed with $75m the company takes a risky asset into the clinic.
The biotech licenses a China-developed anti-B7-H3 ADC.
The Japanese group’s $1.2bn deal with Innovent is by far the biggest of the fourth quarter.
The biggest oncology buy of the quarter concerned the prostate cancer player Halda.
GEN1286 looks dead, though MCLA-129 continues for now.
Takeda picked up IBI363 for $1.2bn, and now Innovent advances IBI3026.
